This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Unilens Modifies License Agreement With Bausch + Lomb - Grants Right To Use Next Generation Multifocal Technology

Stocks in this article: UVIC

LARGO, Fla., April 11, 2013 /PRNewswire/ -- Unilens Vision Inc. (OTC Markets Group OTCQB: UVIC) (TSX Venture Exchange: UVI), through it's wholly owned subsidiary Unilens Vision Sciences Inc. today announced that the company and Bausch + Lomb have extended the parties' existing licensing agreement. 

The amended agreement continues Bausch + Lomb's exclusive worldwide license for Unilens' multifocal technology and grants Bausch + Lomb an exclusive worldwide license to use Unilens' new multifocal technology.  Terms of the arrangement were not disclosed; however the parties have agreed that the existing royalty rates will remain in effect and will apply for both technologies. 

Bausch + Lomb recently introduced the PureVision® 2 for Presbyopia in certain European markets.  The new addition to the PureVision portfolio incorporates Bausch + Lomb's own innovative lens technology, using certain licensed elements of Unilens' next generation technology, resulting in a new contact lens offering exceptional near, intermediate, and distance vision.

"We are very pleased to have licensed our next generation technology to Bausch + Lomb, an industry leading global healthcare company," said Michael Pecora, Unilens President and CEO.  "The licensing agreements, for the worldwide distribution of our proven technology, allows for us to continue focusing our resources on the development and marketing of new and innovative specialty lens products."

Unilens will continue to develop, manufacture, license, and market contact lenses, including its flagship product the C-Vue® Hydravue™ Multifocal, a disposable silicone hydrogel for monthly replacement, as well as a full line of customized silicone hydrogel lenses under the C-Vue HydraVue brand exclusively to independent eye care professionals.

About Unilens Vision Inc. – "The Independent Eye Care Professionals' Contact Lens Company"

Established in 1989, and located in Largo, Florida, Unilens Vision Inc., through its wholly- owned subsidiaries Unilens Corp., USA and Unilens Vision Sciences Inc., develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vuea brand, directly to Independent Eye Care Professionals.  Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Markets Group (OTCQB) under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI".

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements.  For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange.  The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs